Clinical Trials Logo
NCT number NCT03494894
Study type Interventional
Source Centre Hospitalier Intercommunal Creteil
Contact Ralph Epaud, MD
Phone 0415175419
Email ralph.epaud@chicreteil.fr
Status Recruiting
Phase N/A
Start date June 1, 2017
Completion date December 2018

Clinical Trial Summary

Cytobacteriological examination of sputum and bacteriological sampling in the middle meatus.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF) N/A
Completed NCT02449785 - Assessment of Cystic Fibrosis Lung Involvement With UTE Pulse Sequences N/A
Terminated NCT02170025 - Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients Phase 2
Completed NCT02465450 - Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis Phase 2
Recruiting NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Recruiting NCT03335202 - Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis N/A
Completed NCT00903201 - 28 Day Repeat Dose in Cystic Fibrosis Patients Phase 2
Recruiting NCT03181932 - A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients Phase 3
Recruiting NCT02823964 - EASY: Extended Access to Sollpura Over Years Phase 4
Active, not recruiting NCT02721498 - Improving Outcome Measures For Adult CF ACT Trials N/A
Active, not recruiting NCT02730208 - A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation Phase 2
Not yet recruiting NCT02894619 - Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO) N/A
Completed NCT02875366 - A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Phase 4
Completed NCT02564354 - Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation Phase 1
Completed NCT02504827 - Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis Phase 4
Completed NCT02421120 - Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Phase 4
Recruiting NCT02225899 - BioEnergetics and Metabolomics in Cystic Fibrosis N/A
Recruiting NCT02907788 - Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL Study N/A
Completed NCT02212587 - Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex Phase 1
Completed NCT02803944 - Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years N/A